UBS Group Trims Humana (NYSE:HUM) Target Price to $250.00

Humana (NYSE:HUM) had its price target cut by UBS Group from $380.00 to $250.00 in a report issued on Friday, Benzinga reports. They currently have a neutral rating on the insurance provider’s stock.

A number of other brokerages have also recently commented on HUM. Leerink Partners cut shares of Humana from an outperform rating to a market perform rating and dropped their price objective for the stock from $400.00 to $250.00 in a research note on Wednesday, October 2nd. Royal Bank of Canada lifted their price target on Humana from $385.00 to $400.00 and gave the stock an outperform rating in a research report on Thursday, September 5th. Deutsche Bank Aktiengesellschaft reduced their price objective on Humana from $349.00 to $250.00 and set a hold rating on the stock in a research note on Thursday. Stephens lowered Humana from an overweight rating to an equal weight rating and lowered their price objective for the company from $400.00 to $250.00 in a research note on Wednesday, October 2nd. Finally, Cantor Fitzgerald reiterated a neutral rating and issued a $395.00 target price on shares of Humana in a report on Tuesday, October 1st. One analyst has rated the stock with a sell rating, sixteen have given a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Humana currently has a consensus rating of Hold and a consensus price target of $357.24.

Humana Trading Down 0.7 %

Shares of HUM opened at $240.03 on Friday. The firm has a market cap of $28.92 billion, a P/E ratio of 14.95, a price-to-earnings-growth ratio of 2.44 and a beta of 0.50. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.66 and a quick ratio of 1.66. Humana has a 1 year low of $213.31 and a 1 year high of $530.54. The company has a 50 day simple moving average of $337.70 and a two-hundred day simple moving average of $342.89.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share for the quarter, beating the consensus estimate of $5.89 by $1.07. The company had revenue of $29.54 billion during the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a net margin of 1.53% and a return on equity of 16.12%. Humana’s quarterly revenue was up 10.4% on a year-over-year basis. During the same period last year, the company posted $8.94 earnings per share. On average, equities analysts expect that Humana will post 16.01 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.47%. The ex-dividend date is Monday, September 30th. Humana’s payout ratio is 22.04%.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. CarsonAllaria Wealth Management Ltd. increased its holdings in Humana by 111.4% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after buying an additional 39 shares during the period. Hantz Financial Services Inc. purchased a new position in shares of Humana in the 2nd quarter valued at $35,000. Family Firm Inc. bought a new position in shares of Humana in the 2nd quarter worth $37,000. Hollencrest Capital Management purchased a new stake in shares of Humana during the 2nd quarter worth $40,000. Finally, Riverview Trust Co bought a new stake in Humana during the second quarter valued at about $44,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.